Press Room

Prospective Study Shows that Therapy Guided by Biotheranostics’ CancerTYPE ID® Molecular Test Improves Survival in Cancer of Unknown Primary Patients
Biotheranostics is Now the Industry Leading Provider of Genomic Solutions Across the Continuum of Metastatic Cancer Management
Biotheranostics Adds Chief Commercial Officer & VP of Corporate Development
Strategic hiring of industry veterans supports company’s continued growth as a leader in solutions for metastatic cancer
Biotheranostics Expands Its PRÉCIS Biomarker Profiles and Strengthens Its Industry-Leading Solution for Metastatic Cancer
Clinically actionable tumor biomarkers help guide treatment choice
Prospective Study Shows Favorable Overall Survival in Cancer of Unknown Primary Patients With Therapy Directed by Biotheranostics’ CancerTYPE ID®
Poster Discussion at ASCO shows CancerTYPE ID predicted a site of tumor origin in 98 percent of CUP patients
Biotheranostics’ CancerTYPE ID® Shows High Accuracy in a Multi-Site Validation Study and Improved Performance Compared with the Standard of Care in Metastatic Tumor Diagnosis
Results reported at ASCO demonstrate superior accuracy compared with Immunohistochemistry and support diagnostic utility of molecular cancer classification